Segment Information

6 Months Ended

Jun. 30, 2014

Segment Information

Segment Information

Note 7. Segment Information

The Company operates in one business segment, which primarily focuses on the development and global commercialization of genomic based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. As of June 30, 2014, the majority of the Company’s product revenues have been derived from sales of one product, the Oncotype DX breast cancer test.

The following table summarizes total revenues from customers and collaboration partners by geographic region. Product revenues are attributed to countries based on ship-to location. Contract revenues are attributed to countries based on the location of the collaboration partner.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
	(in thousands)
United States	$	58,617	$	54,520	$	114,085	$	109,083
Outside of the United States	11,860		9,171		23,394		17,702
Total revenues	$	70,477	$	63,691	$	137,479	$	126,785